APA (7th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. (2018). CADTH Canadian Drug Expert Committee recommendation: Indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK-Nitisinone - ). Canadian Agency for Drugs and Technologies in Health.

Chicago Style (17th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Indication : The Treatment of Adult and Pediatric Patients with Hereditary Tyrosinemia Type 1 (HT-1) in Combination with Dietary Restriction of Tyrosine and Phenylalanine. Nitisinone (MDK-Nitisinone - ). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018.

MLA (9th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Indication : The Treatment of Adult and Pediatric Patients with Hereditary Tyrosinemia Type 1 (HT-1) in Combination with Dietary Restriction of Tyrosine and Phenylalanine. Nitisinone (MDK-Nitisinone - ). Canadian Agency for Drugs and Technologies in Health, 2018.